Generation of Hematopoietic Stem/Progenitor Cells from Pluripotent Stem Cells for Cellular Therapy
A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Stem Cells".
Deadline for manuscript submissions: closed (15 December 2021) | Viewed by 27513
Special Issue Editor
Special Issue Information
Dear Colleagues,
With Yamanaka’s landmark reprogramming of adult somatic cells into induced pluripotent stem cells (iPSCs) in 2006, the appealing concept of generating iPSCs from an individual patient, correcting the genetic defect and differentiating the disease-free iPSCs into a theoretically infinite supply of transplantable autologous Hematopoietic Stem/Progenitor Cells (HSPCs) arose. However, despite recent promising reports, efficient derivation of functional HSPCs with a robust capability for definitive in vivo engraftment and multilineage potential remains challenging. Therefore, clinically feasible strategies to advance the current state of de novo HSPC generation are needed.
This Special Issue solicits original research manuscripts and review articles on topics related to the generation of HSPCs from pluripotent stem cells (PSCs)—including, but not limited to, developmental hematopoiesis, strategies for HSPC derivation (e.g., directed differentiation, conversion), characterization of PSC-derived hematopoietic cells (e.g., transcriptome, epigenome), hematopoietic disease modelling, genetic correction/editing and differentiation of disease-specific PSCs, etc.
Dr. Andre Larochelle
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- hematopoietic stem cell
- iPSC
- ESC
- pluripotent stem cell
- differentiation
- hematopoiesis
- mesoderm
- gene editing
- gene therapy
- cell therapy
- inherited blood disorder
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.